Tallimustine
Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 115308-98-0
- Formule: C32H38Cl2N10O4
- Masse moléculaire:697.61
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| L1210 | IC50 |
48.9 nM
Compound: tallimustine (TAM)
|
Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)
Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)
|
[PMID: 15115402] |
| L1210 | IC50 |
55.3 nM
Compound: tallimustine (TAM)
|
Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells
Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells
|
[PMID: 15115402] |
Tallimustine (0.1-10 μM, 4 h) induces damage to purified SV40 DNA[1].
Tallimustine (72 h ) shows cytotoxicity in CEM Cells, with an IC50 of 3.5 nM[1].
Tallimustine (25 and 100 nM, 6 days) induces erythroid differentiation of K562 cells[2].
Tallimustine (100 nM, 6 days) increases accumulation of γ-globin mRNA in K562 cells[2].
Tallimustine (0.5 μg/mL, 1 h) arrests SW626 cells in G2/M phase[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:K562 cells
-
Concentration:25 and 100 nM
-
Incubation Time:4 days
-
Result:Inhibited cell proliferation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:L1210 tumor bearing mice[2].
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Prolonged the survival of mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 115308-98-0
-
Masse moléculaire 697.61
-
Formule C32H38Cl2N10O4
-
SMILES
O=C(C1=CC=C(N(CCCl)CCCl)C=C1)NC2=CN(C)C(C(NC3=CN(C)C(C(NC4=CN(C)C(C(NCCC(N)=N)=O)=C4)=O)=C3)=O)=C2
-
Synonyms
FCE 24517
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Herzig MC, et al. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry. 1999 Oct 19;38(42):14045-55. [Content Brief]
[2]. Bianchi N, et al. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. Br J Haematol. 2001 Jun;113(4):951-61. [Content Brief]
[3]. Erba E, et al. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer. 1995 Jul 17;62(2):170-5. [Content Brief]
[4]. Tagliabue G, et al. Combination of the new minor groove alkylator tallimustine and melphalan. Eur J Cancer. 1997 Feb;33(2):284-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tallimustine Related Classifications
HY-105270 Related Classifications
Powered by Bioz